Analysts have recently evaluated Recursion Pharmaceuticals and provided 12-month price targets. The average target is $7.4, ...

The other AI biotech company that Recursion is merging with before early 2025, Exscientia, counts Merck, Sanofi, and Bristol Myers Squibb among its collaborators. Many of the other major players ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals RXRX, revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More Jan. 07, 2025 9:15 ...

Recursion will host a (L)earnings Call on May 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm BST from Recursion’s X (formerly Twitter), LinkedIn, and YouTube accounts giving analysts, investors ...

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More ...

3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock. Alex Carchidi, The Motley Fool . Sat, Oct 26, 2024, 9:00 AM 5 min read. In This Article: ... Enter Recursion, ...